NCT02911402|Completed
Motion Sickness on Astrolabe's Vessel
SICKVEST
Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe
Loading search results
SICKVEST
Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe
Sponsor study identifier
observational
147
1 country
1
Study Start
October 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2017
Actual (reported)Study Completion
December 2018
Actual (reported)Sea sickness syndrome is present for 80% of persons on board when the boat rotation missions Astrolabe, sometimes there is a risk of very significant dehydration. A special unit specialized in the fundamental study of the vestibular system (inner ear), sensory organ at the base of visual-vestibular conflict inducing this syndrome, also provides medical support for parabolic flights (flight reproducing weightlessness) where this syndrome is strongly present. The goal of the study is to assess the frequency of occurrence of this sea sickness syndrome on the Astrolabe, to understand the triggers (type of boat movements, personality traits, anxiety / stress) without changing habits on board for those on board taking a antinaupathique treatment given by the ship's doctor. This study will be done in collaboration between INSERM U 1075 (France) and the Laboratory of military research VIPER specialized in extreme environments (Belgium). The ultimate goal will be to provide the best recommendations and the best treatment regimen to alleviate as best as possible the symptoms of people on board of the Astrolabe so scientists on board can perform their work.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 2014
Date type not reportedThis date has not been verified as actual or estimated.
September 20, 2016
Actual (reported)September 22, 2016
Actual (reported)December 2017
Actual (reported)December 2018
Actual (reported)Motion Sickness susceptibilty questionnaire (fMSSQ)
Sensitivity of motion sickness
day 1 to day 10
STAY-YA questionnaire
anxiety
day 1 to day 10
STAY-YB questionnaire
anxiety
day 1 to day 10
Vis-Morgen Questonnaire about sleeping
Subjective sleep scoring
day 1 to day 10
Fatigue questionnaire
Tiredness
day 1 to day 10
Dietary intake survey
food intake
day 1 to day 10
type of movement from the ship using use the data from the Dynamic Positioning System on board
baseline and every day up to 10 days
data from individual actigraphs worn by the participants
baseline and every day up to 10 days
personnality questionnaire (OCEAN)
baseline and every day up to 10 days
anxiety questionnaire (STAY).
baseline and every day up to 10 days
treatment taken (international denomination and dose)
baseline and every day up to 6 days
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Astrolabe passengers
Caen University Hospital
Caen, 14033, France
stephane Besnard, MD
CaenHU
147 participants (actual enrollment reported by the registry).
First Submitted
September 20, 2016
First Posted
September 22, 2016
Study Start
October 2014
Date type not reportedThis date has not been verified as actual or estimated.
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Contact the study team to confirm eligibility.
Primary Completion
December 2017
Actual (reported)Study Completion
December 2018
Actual (reported)Last Updated
February 15, 2022
Record last verified: 2022-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: